SciVac Therapeutics agrees to acquire VBI Vaccines

Rehovot, Israel-based SciVac Therapeutics announced Monday its intention to acquire VBI Vaccines ($VBIV) to form a commercial-stage company with a licensed hepatitis B vaccine and a pipeline of preventative and therapeutic vaccine candidates. VBI will become a wholly owned subsidiary of SciVac, which will rename itself VBI Vaccines. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.